Literature DB >> 7724476

Sumatriptan absorption from different regions of the human gastrointestinal tract.

P E Warner1, K L Brouwer, E K Hussey, G E Dukes, W D Heizer, K H Donn, I M Davis, J R Powell.   

Abstract

Sumatriptan exhibits low oral bioavailability partly due to presystemic metabolism, which may vary with regional differences in metabolic activity throughout the gastrointestinal tract. This study evaluated sumatriptan absorption in humans after administration orally and by oroenteric tube into the jejunum and cecum. Because the site of cecal administration varied, pharmacokinetic parameters for sumatriptan and its major metabolite were compared statistically only after oral and jejunal administration. One-half of the oral dose was recovered in the urine as parent (3%) and metabolite (46%). Sumatriptan was absorbed throughout the gastrointestinal tract; absorption was similar after oral and jejunal administration, and less after cecal administration. The metabolite AUC and the AUC ratio (metabolite/parent) were significantly lower after jejunal compared to oral administration; the AUC ratio was two-fold lower after cecal administration. Results suggest that presystemic metabolism of sumatriptan varies throughout the gastrointestinal tract and/or regional differences exist in the absorption of metabolite formed within the gastrointestinal tract.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7724476     DOI: 10.1023/a:1016211409315

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  10 in total

Review 1.  Metabolism of drugs and other xenobiotics in the gut lumen and wall.

Authors:  K F Ilett; L B Tee; P T Reeves; R F Minchin
Journal:  Pharmacol Ther       Date:  1990       Impact factor: 12.310

2.  Anti-migraine drugs in development: advances in serotonin receptor pharmacology.

Authors:  P P Humphrey; W Feniuk; M J Perren
Journal:  Headache       Date:  1990-01       Impact factor: 5.887

3.  The influence of variable gastric emptying and intestinal transit rates on the plasma level curve of cimetidine; an explanation for the double peak phenomenon.

Authors:  R L Oberle; G L Amidon
Journal:  J Pharmacokinet Biopharm       Date:  1987-10

4.  Rapid intubation of the ileo-colonic region of man.

Authors:  P Kerlin; R Tucker; S F Phillips
Journal:  Aust N Z J Med       Date:  1983-12

5.  Ranitidine bioavailability and kinetics in normal male subjects.

Authors:  D C Garg; D J Weidler; F N Eshelman
Journal:  Clin Pharmacol Ther       Date:  1983-04       Impact factor: 6.875

6.  Characterization of the enzyme responsible for the metabolism of sumatriptan in human liver.

Authors:  C M Dixon; G R Park; M H Tarbit
Journal:  Biochem Pharmacol       Date:  1994-03-29       Impact factor: 5.858

7.  The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan.

Authors:  P A Fowler; L F Lacey; M Thomas; O N Keene; R J Tanner; N S Baber
Journal:  Eur Neurol       Date:  1991       Impact factor: 1.710

8.  Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine.

Authors:  M F Williams; G E Dukes; W Heizer; Y H Han; D J Hermann; T Lampkin; L J Hak
Journal:  Pharm Res       Date:  1992-09       Impact factor: 4.200

9.  Pharmacokinetics of famotidine in man.

Authors:  H Kroemer; U Klotz
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1987-08

10.  Determination of sumatriptan succinate in plasma and urine by high-performance liquid chromatography with electrochemical detection.

Authors:  P D Andrew; H L Birch; D A Phillpot
Journal:  J Pharm Sci       Date:  1993-01       Impact factor: 3.534

  10 in total
  12 in total

Review 1.  Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications.

Authors:  D Fleisher; C Li; Y Zhou; L H Pao; A Karim
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  Loss of orally administered drugs in GI tract.

Authors:  Yogeshkumar Nanasaheb Gavhane; Adhikrao Vyankatrao Yadav
Journal:  Saudi Pharm J       Date:  2012-04-20       Impact factor: 4.330

Review 4.  The use of gastrointestinal intubation studies for controlled release development.

Authors:  Steven C Sutton
Journal:  Br J Clin Pharmacol       Date:  2009-09       Impact factor: 4.335

5.  Absorption of propranolol in humans following oral, jejunal, and ileal administration.

Authors:  A Buch; W H Barr
Journal:  Pharm Res       Date:  1998-06       Impact factor: 4.200

6.  Absorption and presystemic metabolism of selegiline hydrochloride at different regions in the gastrointestinal tract in healthy males.

Authors:  J S Barrett; P Szego; S Rohatagi; R J Morales; K E De Witt; G Rajewski; J Ireland
Journal:  Pharm Res       Date:  1996-10       Impact factor: 4.200

7.  Protective Roles of N-acetyl Cysteine and/or Taurine against Sumatriptan-Induced Hepatotoxicity.

Authors:  Javad Khalili Fard; Hossein Hamzeiy; Mohammadreza Sattari; Mohammad Ali Eghbal
Journal:  Adv Pharm Bull       Date:  2016-12-22

Review 8.  Sumatriptan-naproxen fixed combination for acute treatment of migraine: a critical appraisal.

Authors:  Chaouki K Khoury; James R Couch
Journal:  Drug Des Devel Ther       Date:  2010-02-18       Impact factor: 4.162

Review 9.  Sumatriptan. An updated review of its use in migraine.

Authors:  C M Perry; A Markham
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

10.  Absorption and presystemic metabolism of nefazodone administered at different regions in the gastrointestinal tract of humans.

Authors:  P H Marathe; D E Salazar; D S Greene; J Brennan; U A Shukla; R H Barbhaiya
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.